Glaucoma co IOptima wins European regulator nod

The company says that its device is safer than the current full manual surgical procedure.

IOptima Ltd. today obtained EU CE Mark certification to sell its laser treatment for glaucoma.

The product, OT-135/P-2, is a laser which thins the scleral tissue of the eyeball, without penetrating it, allowing the intra-ocular fluid to drain through the perforations in membrane, and to reach optimal pressure. The laser automatically stops when the target area become damp, indicating success. The company says that its device is safer than the current full manual surgical procedure - trabeculectomy.

IOptima already has CE Mark for an earlier version of the IOptimate. The company says that the new version is the commercial version of the device and that it will be marketed in the countries where the CE Mark is valid. The company already has several distribution agreements for the device.

IOptima is a portfolio company of Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT). Bio-Light's share price 3.3% today to NIS 0.374, giving a market cap of NIS 34 million.

Published by Globes [online], Israel business news - - on December 15, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017